APA (7th ed.) Citation

Robbrecht, D., Grob, J., Bechter, O., Simonelli, M., Doger, B., Borbath, I., . . . Wang, H. (2024). Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors. CTS: Clinical & Translational Science, 17(2), 1. https://doi.org/10.1111/cts.13736

Chicago Style (17th ed.) Citation

Robbrecht, Debbie, et al. "Biomarker and Pharmacodynamic Activity of the Transforming Growth Factor‐beta (TGFβ) Inhibitor SAR439459 as Monotherapy and in Combination with Cemiplimab in a Phase I Clinical Study in Patients with Advanced Solid Tumors." CTS: Clinical & Translational Science 17, no. 2 (2024): 1. https://doi.org/10.1111/cts.13736.

MLA (9th ed.) Citation

Robbrecht, Debbie, et al. "Biomarker and Pharmacodynamic Activity of the Transforming Growth Factor‐beta (TGFβ) Inhibitor SAR439459 as Monotherapy and in Combination with Cemiplimab in a Phase I Clinical Study in Patients with Advanced Solid Tumors." CTS: Clinical & Translational Science, vol. 17, no. 2, 2024, p. 1, https://doi.org/10.1111/cts.13736.